用于抑制炎症性细胞因子生产的素的结构-活性关系分析
Yohei Takenaka1, Ryu Tanaka2, Kazuki Kitabatake1
1Department of Radiation Biosciences, Graduate School of Pharmaceutical Sciences, Tokyo University of Science.
Biological & pharmaceutical bulletin
|May 12, 2024
概括
选择性血清素再吸收抑制剂 (SSRI) 显示出抗炎作用. 富洛克塞提因 (Fluoxetine) 是一种药物.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- 作为抗抑郁药物使用的选择性血清素再吸收抑制剂 (SSRI) 对COVID-19等炎症性疾病具有潜在的益处.
- 素 (FLX) 之前被确定为抑制互白素-6 (IL-6) 生产的最强效SSRI.
研究的目的:
- 为了研究fluoxetine (FLX) 关于其抗炎性能的结构-活性关系.
- 确定FLX的关键结构特征,这些特征负责其对巨细胞IL-6产生的抑制作用.
主要方法:
- 使用的J774.1小鼠巨细胞被TLR3激动剂多诺辛酸-多西酸 (poly(I:C)) 刺激.
- 合成并测试了各种FLX衍生物,以评估它们对IL-6产生的影响.
- 确定FLX及其衍生品的IC50值.
主要成果:
- 素抑制了由多I:C诱导的IL-6产生,其IC50为4.76μM.
- 一种用替代的FLX衍生物缺乏抗炎活性,这凸显了甲基胺基组的重要性.
- 含有N-或N-(pyridin-3-yl) 甲基的衍生品保持了显著的活性,而其他衍生品则表现出减少或完全没有活性.
- 对于TLR3和TLR9通路的结构-活性关系是相似的,但TLR4通路对氨基组修饰的反应是不同的.
结论:
- 素的原子上的替代物显著调节其抗炎活性.
- 甲基胺基组对于FLX的抗炎作用对TLR3介导的IL-6产生至关重要.
- FLX衍生物表现出不同的疗效,这取决于涉及的特定的Toll-like受体通路.
更多相关视频
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131
Antidepressant Drugs: MAOIs and Other Agents
226
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
226
Structure-Activity Relationships and Drug Design
701
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
701
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
115
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
115
Inflammatory Response
2.0K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
2.0K


